Piper Sandler Boosts Enfusion (NYSE:ENFN) Price Target to $11.50

Enfusion (NYSE:ENFN) had its price objective increased by equities researchers at Piper Sandler from $10.00 to $11.50 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Piper Sandler’s price target suggests a potential upside of 8.70% from the stock’s previous close.

Separately, Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.25.

Enfusion Stock Performance

Shares of ENFN opened at $10.58 on Monday. Enfusion has a one year low of $7.52 and a one year high of $11.38. The stock has a 50-day moving average price of $9.74 and a 200 day moving average price of $9.02. The company has a market capitalization of $1.36 billion, a P/E ratio of 264.57, a P/E/G ratio of 3.98 and a beta of 0.97.

Insiders Place Their Bets

In other Enfusion news, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now owns 1,143,544 shares in the company, valued at $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 36.44% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enfusion

Institutional investors have recently modified their holdings of the business. Arizona State Retirement System acquired a new position in shares of Enfusion during the second quarter valued at $86,000. Harbor Capital Advisors Inc. boosted its stake in Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares during the period. Belvedere Trading LLC bought a new position in Enfusion in the 3rd quarter worth about $114,000. Paloma Partners Management Co acquired a new stake in shares of Enfusion in the third quarter valued at approximately $157,000. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Enfusion by 27.7% during the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after buying an additional 4,239 shares during the last quarter. Institutional investors own 81.05% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.